DelveInsight Blogs Sitemap

All Posts in this category
S.No. Product Name Actions
1 Pfizer to acquire Arena Pharma; Takeda's 'Wave 2' multiple myeloma med data; Novartis's next-gen CAR-Ts clinical data; Roche unveils Avenio system Visit Post
2 CAR-T Cell Therapy aka Miraculous Technology: Mapping the Market, Approved Therapies, Competitive Landscape and Impact of COVID-19 Visit Post
3 Avrobio’s Gene Therapy for Cystinosis Treatment: A New Hope to Overcome the Existing Medical Unmet Needs Visit Post
4 The Evolved Gene Therapy for Hemophilia Visit Post
5 Analyzing the Key Companies and the Emerging Gene Therapy in the Dermatology Segment Visit Post
6 Development of Gene Therapies in Dermatology Visit Post
7 Pfizer tightens DMD trial criteria over safety concerns; Kytopen raises $30M; Eli Lilly taps Reify's Care Access; Vensana Capital raises $325M Visit Post
8 Intratumoral Cancer Therapy: A Potential Weapon To Fight the Battle Against Cancer Visit Post
9 BlueRock secures FDA fast track; Omniscient rakes in $29M; Neuspera’s nerve implant gets a $65M boost Rivus’ therapy nabs $35M Visit Post
10 Arrowhead's ARO-ENaC Clinical Trial; Sartorius Acquires Stake in CellGenix; AGC Biologics's Cell & Gene Therapy; Sirnaomics Secures $105 Million Visit Post
11 Intellia's Quest with CRISPR; Innovent, Synaffix ADC Tech Deal; Lilly's Diabetes Blockbuster Tirzepatide; Polyphor’s Bleak Future Visit Post
12 Insilico Medicine raises $255M; Sanofi & Translate Bio initiate trial; Medtronic gains expanded FDA approval; Blackstone, Cellex & Intellia form CAR-T startup Visit Post
13 Horizon/ Arrowhead Deal; Dr Reddy's Lab’s Drug US Launch; Targovax’s ONCOS-102; RedHill's Oral Opaganib in COVID-19 Visit Post
14 Mallinckrodt earns FDA nod for skin therapy; RayzeBio secures $108M; VectorY raises $38M; Umoja banks $210M Visit Post
15 Aelis Farma pockets $30M; Alcyone unveils $23M for AAV gene therapies; Progentec and GSK collaborate; Kozin bags $60M Visit Post
16 Biogen’s Alzheimer’s Drug; FDA approval to Novo Nordisk’s Wegovy; Bluebird's Gene Therapy Visit Post
17 Pieris-Genentech deal; Xilio inks deal with Merck; BMS taps Xencor's tech; GenSight's gene therapy reports partial recovery Visit Post
18 Ocugen-Bharat Biotech’s Covaxin Against B.1.617 Corona Variant; uniQure Shares; J&J Covid Vaccine; Sanofi-Moderna COVID Vaccine Deal Visit Post
19 Vertex leads in CRISPR Therapeutics deal; Update for Phase 2 clinical trial of KVD824; Ovid dumps lead program; Virta Health pulls in $133M Visit Post
20 Lilly’s Retevmo shows promise; CeQur tanks up on $110M in funding; Repertoire secures $189M; Recursion sets terms for $306M IPO Visit Post
21 Biohaven's Troriluzole Failure; Daiichi/ AZ's Enhertu; Fujifilm & Manufacturing Spree; J&J's Darzalex Faspro Visit Post
22 Fosun-BioNTech's COVID-19 vaccine; Multiple Sclerosis research update; Vosoritide nabs FDA review; FDA nods to paclitaxel-coated Ranger balloon for PAD Visit Post
23 Novartis taps Molecular Partners to combat COVID-19; GSK culls phase 2 asthma drug; Exact Sciences acquires Thrive for $ 2.15 B; EQRx-CStone's deal for checkpoint inhibitors Visit Post
24 Bayer eyes AskBio’s Gene Therapies; Novartis' Iptacopan; Forma's IDH1-Mutated AML Therapy; EpicGenetics teams up with Mayo Clinic Visit Post
25 GSK's RSV vaccine; SparingVision's interest in gene therapy; InCarda's raise; BridgeBio's R&D deal Visit Post
26 Amylyx's neuron-protecting drug slows ALS decline; Antisense drugs could help fight ALS and dementia; CAR-T research updates; Orca and Lyell announces research partnership Visit Post
27 FDA rejects BioMarin's Valoctocogene Roxaparvovec; J&J inks $6.5B deal; Alzheon bags $47M; Research updates on diabetes Visit Post
28 Startup focuses tumors with CAR-T; AbCellera grabs USD 105M; Gilead inks USD 2B deal; GSK’s anti-BCMA antibody receives a boost Visit Post
29 CanSino deals with Precision; Atea raises USD 215 M; Applied Molecular Transport targets for USD 100 M IPO; Cell therapy repairs multiple sclerosis in mice Visit Post
30 CAR-T cell therapy market for Non-Hodgkin lymphoma: Future prospects, and untapped opportunities Visit Post
31 Future Perspectives Of CAR-T Cell Therapy Market In Acute Lymphoblastic Leukemia (ALL) Visit Post
32 CAR-T in killing tumors; Amunix raises $73M; Autism findings in protein-targeted treatment Visit Post
33 Gene therapy might make cocaine less addictive Visit Post
34 Why should every company working on CAR-T therapy attend CAR TCR Summit Europe? Visit Post
35 In a blind race to cure HIV, can Gene therapy be a deal-breaker? Visit Post
36 Autologous cell therapy market: A new paradigm for kidney diseases Visit Post
37 Japan is transforming its Healthcare sector through Regenerative Medicine Visit Post
38 Zogenix acquires Modis Therapeutics; Amgen buys Otezla; CRISPR slows down the Breast cancer rate Visit Post
39 Notizia Visit Post
40 Notizia Visit Post
41 Notizia Visit Post
42 Can commoners afford to spend million dollars on GENE Therapy? Visit Post
43 Gene Therapy in Oncology: Innovation to Commercialization Visit Post
44 Inozyme Raises $67M; Shanghai Miracogen partners with Synaffix; EdiGENE raises $15M; Antengene announces its expansion Visit Post
45 The promising Pipeline for Gene Therapy In Oncology Visit Post
46 Notizia Visit Post
47 The Business Cocktail Visit Post
48 BioNTech lines up $800M; Deerfield remunerates; Britain's Smith & Nephew to acquire Osiris Visit Post
49 The Business Cocktail Visit Post
50 Notizia Visit Post
51 A CRISPR WAY TO USE STEM CELLS Visit Post
52 CRISPR proves to be a blessing for LASSA fever Visit Post
53 Notizia Visit Post
54 Human cells reprogrammed to create insulin in diabetic mice Visit Post
55 Neurogene raises $68.5M; AbbVie and Teneobio sign deal; 5AM Ventures nets Visit Post
56 Genentech remunerates Xencor; XPrize upraises fund; GSK gambles Visit Post
57 Notizia Visit Post
58 Molecular Profiling Could Help in Early Lung Cancer Detection: Study Visit Post
59 Highly mutated cancers respond better to immune therapy Visit Post
60 Notizia Visit Post
61 Where in the world could the first CRISPR baby be born? Visit Post
62 Vedanta raises; Relay Therapeutics reels in; Gene therapy for SMA Visit Post
63 66 Year Ohio Woman Becomes Cancer Free, Thanks to CAR T Cell Therapy Visit Post
64 Baby gene edits could affect a range of traits Visit Post
65 Cancer Cells Trick Body’s Immunity to Survive against Treatment Visit Post
66 Researchers say CRISPR edits to a human embryo worked Visit Post
67 Synthorx needs IPO; Deerfield puts up $80M; SVB remunerates; Celgene’s deal Visit Post
68 Gilead remunerates; Roche taps Halozyme’s drug delivery tech; Orchard Therapeutics prices its IPO Visit Post
69 Novartis signs; Sosei passes; Amgen remunerates; J&J remunerates for RSV drug Visit Post
70 Is Gene Therapy the Next Cancer Treatment Revolution?  Visit Post
71 Hologic complements Focal; Allogene for IPO; Gamida, Novartis-backed cell therapy startup; Aduro loses partner Visit Post
72 Epic Sciences garners; Tvardi gets financing; Galera raises; Fund for cancer research Visit Post
73 Pancreatic Cancer Treatment to Stride Beyond Chemotherapy Visit Post
74 4D Molecular Therapeutics raises; Arvinas slates for IPO; Sutro ruminates for $ 75M; Emergent BioSolutions remunerates Narcan maker Visit Post
75 Snippet Visit Post
76 The Business Cocktail(Therapeutics) Visit Post
77 Personalized Medicine Approach: An Upholding Paradigm for a Promising and futuristic Patient Centric Health Care Visit Post
78 Sarepta’s deal; Fund raisings for Apexigen; Novo funded rare disease startup Visit Post
79 Snippet : Genetic Mutation Visit Post
80 Idera's drug; CRISPR increase risk; Juvenescence grabbed USD 50M; AstraZeneca, Lilly terminates Visit Post
81 Axovant rely on gene therapy; CAR-T treatments; Pfizer’s dacomitinib; Adaptimmune construct manifestation Visit Post
82 Hematopoietic Stem Cell Transplantation Visit Post
83 Atara Biotherapeutics hires; Minor effects of multiple genes determine migraine risk; Celgene set to refile ozanimod Visit Post
84 Horizon Discovery declines Abcam’s USD 367 million takeover bid Visit Post
85 Phase 1 data of CYC065; Lysogene delays phase 3 study; Genetic disorders Diagnosis; PD-1 resistance in melanoma patients Visit Post
86 Cellectis successfully bags USD 164 million for Gene-editing and CAR-T programs Visit Post
87 Notizia Visit Post
88 Business Cocktail Visit Post
89 Business Cocktail Visit Post
90 Pandion bags $58M; Carmot Therapeutics grabs $15M; Innovent looks for IPO; Collaboration of Sandoz & Biocon Visit Post
91 Snippet Visit Post
92 Notizia Visit Post
93 NOTIZIA Visit Post
94 Novartis ventures; Bill Gates invests; Arcus Biosciences gains; Denali and Odonate seek funding; Fosun Pharma acquires Visit Post
95 Natural Killer Cell Therapies– Advancing technology increasing competition among the companies Visit Post
96 South Korean researchers influencing lift of human-embryo restrictions Visit Post
97 CAR-T Phase I trials; ContraVir Announces; Merck acquired; Excision BioTherapeutics bags $10M Visit Post
98 Social Behavior Loss Observed in Gene-edited ants through CRISPR Visit Post
99 Natural Killer Cell Therapies– Advancing technology increasing competition among the companies Visit Post
100 Bristol-Myers Squibb to nix; Pfizer commits $100M; Merck and GSK production issues; Shire unloads plant Visit Post
101 Geneticists enlist engineered virus & CRISPR to battle citrus disease Visit Post
102 Cord Blood makes brains of elderly mice young again Visit Post
103 Novartis gets CAR-T drug; Shire aims to block; Xeljanz stands; Payer snubs; Lawmakers pass a bill Visit Post
104 CRISPR finds faults in previous researches Visit Post
105 Medical tourism in India Visit Post
106 Sanofi sues Novo; Allergan gets help; Actelion snubs; Impax CEO Wilkinson out Visit Post
107 Science Events of the Year Visit Post
108 Mexico's Human-Embryo Research on Tenterhooks Visit Post
109 NgAgo gene-editing, claiming to be a better alternative to CRISPR gene editing, falls into a controversy in peer-reviewed papers Visit Post
110 CRISPR gene-editing tested in a person for the first time Visit Post
111 Antibody-Drug Conjugate and Big Pharmaceutical Companies Visit Post
112 What are your views on Gene Therapy? Visit Post
113 Antibody-Drug Conjugate Market Outlook, 2015 Report in Market Now! Visit Post
114 Next Generation Antibody-Drug Conjugate Therapeutics and Market Analysis Visit Post
115 Antibody-Drug Conjugates Market Outlook, 2015 Report Visit Post
116 Antibody–Drug Conjugates: An Emerging Concept in Cancer Therapy Visit Post
117 Gene Therapy to “Assassinate” HIV virus Visit Post
118 Suicide Gene Therapy: Where do we stand? Visit Post
119 DelveInsight’s Gene Therapy Reports: Launched Visit Post
120 A CRISPR-Cas9 approach for Gene Therapy: The Hot New R&D Field! Visit Post
121 Gene Therapy’s Emergence: The “New” approach for Huntington’s disease Visit Post
122 Are you ready to embrace Gene Therapy? Visit Post
123 DelveInsight’s Ophthalmologic disorders based Gene Therapy Reports Visit Post
124 DelveInsight’s Hematological disorders based Gene Therapy Reports Visit Post
125 DelveInsight’s Respiratory disorders based Gene Therapy Reports Visit Post
126 DelveInsight’s Immunology based Gene Therapy Reports Visit Post
127 DelveInsight’s Cardiovascular disorders based Gene Therapy Reports Visit Post
128 DelveInsight’s Musculoskeletal disorders based Gene Therapy Reports Visit Post
129 DelveInsight’s Metabolic disorders based Gene Therapy Reports Visit Post
130 DelveInsight’s Infectious disorders based Gene Therapy Reports Visit Post
131 DelveInsight’s Gastrointestinal based Gene Therapy Reports Visit Post
132 DelveInsight’s Genetic disorders based Gene Therapy Reports Visit Post
133 DelveInsight’s Dermatology based Gene Therapy Reports Visit Post
134 DelveInsight’s Genitourinary Sex hormones based Gene Therapy Reports Visit Post
135 DelveInsight’s Central Nervous System Disorders based Gene Therapy Reports Visit Post
136 DelveInsight’s Otolaryngology based Gene Therapy Reports Visit Post
137 DelveInsight’s Oncology based Gene Therapy Reports Visit Post
138 Break the Gene Therapy Barrier with DelveInsight’s Gene Therapy Reports Visit Post
139 Gene Therapy Market Visit Post